Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors.

Cell reports. Medicine - 20 Jul 2021

Portelinha Ana, Thompson Scott, Smith Roger A, Da Silva Ferreira Mariana, Asgari Zahra, Knezevic Andrea, Seshan Venkatraman, de Stanchina Elisa, Gupta Sandeep, Denis Louis, Younes Anas, Reddy Sanjeeva

Abstract excerpt

Inhibition of the extracellular signal-regulated kinases ERK1 and ERK2 (ERK1/2) offers a promising therapeutic strategy in cancers harboring activated RAS/RAF/MEK/ERK signaling pathways. Here, we describe an orally bioavailable and selective ERK1/2 inhibitor, ASN007, currently in clinical development for the treatment of cancer. In preclinical studies, ASN007 shows strong antiproliferative activity in tumors...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Extracellular Signal-Regulated MAP Kinases
Share to Inhibitory Concentration 50

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, Nude

Share to Phosphatidylinositol 3-Kinases

Share to Pyrimidines

Share to Quinazolines

Share to raf Kinases

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 34337566
DOI: 10.1016/j.xcrm.2021.100350
PMCID: PMC8324497

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors.PMID 34337566Read ↗

ERK Inhibitor ASN007 Effectively Overcomes Acquired Resistance to EGFR Inhibitor in Non-small Cell Lung CancerSemantic proximity Read ↗

ERK inhibitor ASN007 effectively overcomes acquired resistance to EGFR inhibitor in non-small cell lung cancer.Semantic proximity Read ↗

ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERKSemantic proximity Read ↗

AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS -Mutant Tumor Models when Combined with the MEK Inhibitor, SelumetinibSemantic proximity Read ↗

RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.Semantic proximity Read ↗

Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.Semantic proximity Read ↗

ERK Inhibition: A New Front in the War against MAPK Pathway-Driven Cancers?Semantic proximity Read ↗

Recent developments in anti-cancer agents targeting the Ras/Raf/ MEK/ERK pathway.Semantic proximity Read ↗

Discovery of a highly potent pan-RAF inhibitor IHMT-RAF-128 for cancer treatment.Semantic proximity Read ↗

The Discovery of Exarafenib (KIN-2787): Overcoming the Challenges of Pan-RAF Kinase Inhibition.Semantic proximity Read ↗

Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF.Semantic proximity Read ↗

Discovery of a highly potent pan-RAF inhibitor IHMT-RAF-128 for cancer treatmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.